Overview

• Sanofi has committed at least $20 billion to US factories and research by 2030, responding to tariff and pricing threats from Donald Trump.
• The French Economy Minister labeled the move a 'bad signal,' emphasizing the need for investment in Europe and France.
• Labor unions warn of a potential shift of research and production to the US, risking Europe's pharmaceutical industry strength.
• Sanofi's announcement follows similar US investment pledges by global pharmaceutical firms like Novartis and Eli Lilly under US geopolitical pressure.
• Despite no immediate cuts to French investments, concerns grow over a gradual reallocation of resources to more profitable markets like the US.